Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects
- 10 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Drug Investigation
- Vol. 41 (7), 639-645
- https://doi.org/10.1007/s40261-021-01052-3
Abstract
Background and Objective Omecamtiv mecarbil (OM) is a cardiac myosin activator under clinical development for the treatment of heart failure. Two modified-release (MR) novel OM minitablet formulations were developed to support the planned investigation of chronic heart failure in pediatric patients. The primary objective of this study was to determine the bioavailability of the minitablets relative to the adult matrix MR formulation tablets. Methods In a randomized, 5-period, crossover study, 20 healthy subjects received each of the following treatments orally: one 25-mg adult matrix MR tablet, 25 1-mg slow-release minitablets, 25 1-mg fast-release minitablets, six 1-mg slow-release minitablets, or six 1-mg fast-release minitablets after an overnight fast of at least 10 h with a minimum washout of 7 days between treatments. Blood samples were collected for up to 168 h. OM pharmacokinetic parameters were estimated using non-compartmental methods. Results When OM was administered as 25 1-mg OM slow-release minitablets, AUClast, AUCinf, and Cmax were 0.998-, 1.00-, and 1.29-fold of a single 25-mg OM matrix MR tablet, respectively. When OM was administered as 25 1-mg OM fast-release minitablets, AUClast, AUCinf, and Cmax were 1.26-, 1.25-, and 2.21-fold of a single 25-mg OM matrix MR tablet, respectively. The slow- and fast-release minitablets display approximately dose-proportional pharmacokinetics. There were no serious adverse events or treatment-emergent adverse events leading to discontinuation from the study. Conclusions Relative bioavailability of slow-release minitablets was demonstrated to be similar to the adult matrix MR formulation.Funding Information
- Amgen
This publication has 12 references indexed in Scilit:
- Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trialsEuropean Journal of Heart Failure, 2020
- Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection FractionJACC: Heart Failure, 2020
- Current State of Pediatric Heart FailureChildren, 2018
- Pediatric Heart Failure: A Practical Guide to Diagnosis and ManagementPediatrics & Neonatology, 2017
- Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2016
- Pediatric Drug Formulations: A Review of Challenges and ProgressPEDIATRICS, 2014
- Favorable Acceptance of Mini-Tablets Compared with Syrup: A Randomized Controlled Trial in Infants and Preschool ChildrenThe Journal of Pediatrics, 2013
- Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man studyThe Lancet, 2011
- Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart FailureScience, 2011
- A novel approach to improve cardiac performance: cardiac myosin activatorsHeart Failure Reviews, 2009